Paper Details

  1. Home
  2. Paper Details

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.

Author: KangYubin, MathewsParker, WangXiaobei, WuJian, ZhangMin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Retinoid X receptor (RXR) agonists were investigated for their potential to enhance the anti-myeloma activity of lenalidomide. The study found that RXR agonists increased CRBN expression, killing myeloma cells and enhancing T-cell function.
Paper Details　
Original Abstract of the Article :
Retinoid X receptor (<i>RXR</i>) heterodimerizes with the <i>PPAR</i> nuclear hormone receptor and regulates its downstream events. We investigated the effects of <i>RXR</i> agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide's anti-myeloma activity, T cell functions, and the le...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417536/

データ提供：米国国立医学図書館（NLM）

RXR Agonists: Boosting Lenalidomide's Anti-Myeloma Activity

Multiple myeloma is a challenging cancer that requires innovative treatment strategies. This study delves into the potential of RXR agonists, a class of drugs that interact with nuclear hormone receptors, to enhance the effectiveness of lenalidomide, a common treatment for multiple myeloma. The authors explore the synergistic effects of this combination, like two desert explorers working together to overcome a treacherous obstacle.

RXR Agonists Enhance Lenalidomide's Anti-Myeloma Activity and T-Cell Function

This study demonstrates that RXR agonists can enhance lenalidomide's anti-myeloma activity by increasing CRBN expression and killing myeloma cells. They also found that RXR agonists can improve T-cell function, a crucial part of the immune response against cancer.

New Hope for Multiple Myeloma Patients: A Combination Approach

This study offers a glimmer of hope for multiple myeloma patients by suggesting that combining RXR agonists with lenalidomide can improve treatment outcomes. It underscores the importance of exploring new treatment strategies and combinations to combat this challenging disease.

Dr.Camel's Conclusion

This study highlights the importance of collaborative research and innovative approaches to cancer treatment. The findings suggest that RXR agonists hold significant potential as a therapeutic strategy for multiple myeloma, much like a hidden oasis offering respite from the harsh desert conditions.
Date :
  1. Date Completed 2023-08-14
  2. Date Revised 2023-08-15
Further Info :

Pubmed ID

37566072

DOI: Digital Object Identifier

PMC10417536

Related Literature

Article Analysis
・Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.